Luc enters depression treatment IP licensing deal with Novartis

23-10-2015

Luc enters depression treatment IP licensing deal with Novartis

KieferPix / Shutterstock.com

Biotechnology company Luc Therapeutics has agreed to licence its intellectual property covering its depression treatment to Novartis, stating that it will accelerate its programme into how to help people living with psychiatric diseases.


Luc Therapeutics; Novartis; biotechnology; depression; intellectual property

LSIPR